Deals: Page 2

  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Gene editing

    AstraZeneca to acquire gene editing biotech LogicBio

    Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.

    By Oct. 3, 2022
  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Emerging biotech

    Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup

    The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a startup run by a former Sarepta executive.

    By Sept. 30, 2022
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • A brown and gray-haired man smiles at the camera.
    Image attribution tooltip
    Permission granted by Ventus Therapeutics

    Ventus sells its lead drug candidate to Novo Nordisk

    The biotech will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.

    By Sept. 29, 2022
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images

    Roche pays $70M in another bid to catch up on cancer cell therapies

    Rival companies have set a standard in lymphoma and leukemia. Now the Swiss drugmaker wants to be a pioneer in cell treatments for solid tumors.

    By Sept. 27, 2022
  • A photo of a Seattle Genetics laboratory
    Image attribution tooltip
    Permission granted by Seagen

    Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

    While a long-rumored acquisition by Merck & Co. still hasn’t materialized, Seagen is forging ahead with a deal of its own, grabbing rights to a bispecific antibody drug from Lava Therapeutics. 

    By Sept. 26, 2022
  • Red human heart drawing on blue background
    Image attribution tooltip
    Jolygon via Getty Images

    AstraZeneca gives up on Ionis’ RNA drug for heart disease

    The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing. 

    By Sept. 23, 2022
  • Illustration of a macrophage devouring a cancer cell.
    Image attribution tooltip
    Design Cells via Getty Images
    Emerging biotech

    Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street

    The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected its top drug last year. 

    By Sept. 21, 2022
  • gene therapy
    Image attribution tooltip
    Stock via Getty Images

    Rocket gives struggling gene therapy company a lifeline after SPAC merger

    Rocket is acquiring Renovacor at a roughly 75% discount to its public debut price last year, when it became one of dozens of biotechs to merge with a blank check company, or SPAC. 

    By Sept. 20, 2022
  • An image of liver cirrhosis
    Image attribution tooltip
    klickit24 via Getty Images

    GenFit, continuing rebuild, buys startup Versantis

    The French company, still aiming to rebound from a Phase 3 study failure two years ago, will pay about $41 million for Versantis and its experimental liver disease drugs. 

    By Sept. 19, 2022
  • A 3D illustration of human lungs.
    Image attribution tooltip
    yodiyim via Getty Images

    Theravance, flush with royalty cash, buys shares from GSK

    The planned transaction will further unwind the respiratory disease company’s relationship with GSK, which dates back two decades.

    By Sept. 19, 2022
  • A stock image of a calculator alongside financial numbers
    Image attribution tooltip
    atiatiati via Getty Images

    After safety setbacks, job cuts, Imara sells its top drug to a startup

    The biotech, which has lost nearly all of its value since going public in 2020, reached a deal to sell a drug it tested in sickle cell disease to Cardurion Pharmaceuticals, a richly funded company focused on cardiovascular research.

    By Kristin Jensen • Sept. 8, 2022
  • Image attribution tooltip
    Courtesy of Roche

    Roche to pay $250M for Good Therapeutics and its targeted drug technology

    The team behind the Seattle-based startup will launch a new company, Bonum Therapeutics, after the sale to Roche is completed.

    By Kristin Jensen • Sept. 7, 2022
  • A sign that says Illumina is on a curb in front of red brick buildings.
    Image attribution tooltip
    Courtesy of Illumina

    Illumina’s hold on Grail depends now on separate appeals in US, Europe

    While it plans to appeal this week’s EC decision, Illumina say it’s preparing for ‘strategic alternatives’ to its acquisition of early cancer detection firm Grail.

    By Elise Reuter • Updated Sept. 6, 2022
  • A person wearing safety goggles holds a pipette of fluid.
    Image attribution tooltip
    Courtesy of Grail

    Judge rules in favor of Illumina, countering FTC concerns over Grail merger

    The ruling makes it more likely Illumina can retain its former subsidiary, which makes cancer diagnostics. The dispute is an important test case for the agency’s plans to more closely scrutinize life sciences mergers. 

    By Elise Reuter , Ricky Zipp • Sept. 2, 2022
  • A 3D illustration of sickle cell anemia disease blood cells
    Image attribution tooltip
    Stock/Ezume Images via Getty Images

    With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug

    The target company, Forma Therapeutics, started as a developer of cancer drugs but has made the most progress in rare blood disorders, attracting Novo’s attention.

    By Updated Sept. 6, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Emerging biotech

    Biotech startup Ocean pivots from IPO to SPAC merger

    The blank-check deal gives Ocean another route to public markets after it struggled to price an initial public offering it revealed back in June 2021.

    By Aug. 31, 2022
  • A photo people walking past the London Stock Exchange.
    Image attribution tooltip
    Scott Barbour / Staff via Getty Images

    Neurocrine, with latest deal, gets a foothold in Europe

    The neuroscience-focused company has agreed to buy U.K.-based Diurnal for around $57 million, a move it expects to “accelerate the establishment of its clinical development and commercial activities” in Europe.

    By Aug. 30, 2022
  • Image attribution tooltip
    Jacob Bell

    Novartis begins plans to spin off generic drug business

    After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

    By Aug. 25, 2022
  • Photo of a woman taking eye drops.
    Image attribution tooltip
    privetik via Getty Images

    Aerie’s glaucoma drug journey ends in $770M sale to Alcon

    The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales. 

    By Aug. 23, 2022
  • Disc Medicine CEO John Quisel
    Image attribution tooltip
    Permission granted by Disc Medicine

    Gemini’s fall gives Disc a way around biotech’s IPO slump

    The biotech’s failed attempt to develop an eye drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets.

    By Aug. 10, 2022
  • A sign for Pfizer is seen outside the Pfizer headquarters on November 9, 2020 in New York City.
    Image attribution tooltip
    David Dee Delgado via Getty Images

    Pfizer buys sickle cell drugmaker Global Blood for $5.4B

    The acquisition gives Pfizer access to Oxbryta, an approved drug for the blood condition, as well as two experimental medicines.

    By , Updated Aug. 8, 2022
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    How a small UK biotech ended up in Gilead’s hands

    MiroBio, which was spun out of the University of Oxford three years ago, drew Gilead’s interest with its autoimmune disease research.

    By Aug. 5, 2022
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.

    Amgen bets almost $4B on a biotech and its inflammation drugs

    The deals hands Amgen a few clinical programs and a marketed therapy in Tavneos, which was approved last year to treat a group of autoimmune diseases.

    By Aug. 4, 2022
  • A white lab coat showing an AbCellera logo
    Image attribution tooltip
    Courtesy of AbCellera

    AbCellera inks another venture partnership, this time with Atlas

    One week after striking a deal with Versant, the antibody specialist is teaming up with Atlas to provide drug candidates to an undisclosed startup backed by the biotech investor.

    By Aug. 3, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip

    AbbVie, targeting a well-known protein family, expands a partnership into neuroscience

    It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

    By Aug. 2, 2022